Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Measurable residual disease (MRD) analysis using circulating tumor DNA (ctDNA) is a non-invasive method of response assessment in large B-cell lymphoma (LBCL), but data supporting its real-world feasibility and performance are needed. We conducted a multicenter, retrospective study of patients with LBCL assessed in rea...

Patrick Gould, D. Coskey, Xin Ma et al. · 0 citations
Open access Aug 2026

A Real‐World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B‐Cell Lymphoma

Data for the use of rituximab, gemcitabine, and oxaliplatin (R‐GemOx) for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R‐GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal F...

L. Budde, A. Olszewski, Bei Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.